AI and multimodal testing are transforming how clinical trials are designed and how new therapies are developed. This session demonstrates how digital models that integrate genomic, transcriptomic and immune data, supported by CLIA/CAP-accredited laboratory capabilities, can identify patient subgroups, guide biomarker discovery and inform treatment strategies. By applying AI driven analysis and digital twin approaches, these tools bring greater precision, adaptability and efficiency to trial design. Additionally, complex multiomic solutions are distilled into clinically deployable patient selection criteria that can be measured with standard of care diagnostic approaches. Attendees will learn how multimodal platforms, anchored by CLIA CAP laboratory rigor, enhance predictions, lower trial risk and accelerate drug development, shaping the next generation of data driven clinical research and advancing the promise of personalized medicine.
